Oncogenic KRAS Desensitizes Colorectal Tumor Cells to Epidermal Growth Factor Receptor Inhibition and Activation

Epidermal growth factor receptor (EGFR)-targeting therapeutics have shown efficacy in the treatment of colorectal cancer patients. Clinical studies have revealed that activating mutations in the KRAS protooncogene predict resistance to EGFR-targeted therapy. However, the causality between mutant KRA...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: van Houdt, Winan J, Hoogwater, Frederik JH, de Bruijn, Menno T, Emmink, Benjamin L, Nijkamp, Maarten W, Raats, Danielle AE, van der Groep, Petra, van Diest, Paul, Borel Rinkes, Inne HM, Kranenburg, Onno
Formato: Artigo
Idioma:Inglês
Publicado em: Neoplasia Press Inc. 2010
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2887497/
https://ncbi.nlm.nih.gov/pubmed/20563247
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados